Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...
Cingulate has filed proposed terms for a $50 million IPO. The firm is seeking to develop improved drug delivery technologies and pair them with existing approved drugs for ADHD. CING is working in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback